← Leaderboards
William C Burhans
Roswell Park Cancer Institute Corp
$1,925,563
Attributed
$1,925,563
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,925,563 · 4
By mechanism
R01$1,900,648 · 3
R03$24,915 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Maria R Baer$1,593,414
- Carl W Porter$5,047,582
- Martin L Brecher$381,449
- Nithya Ramnath$1,296,527
- Meir Wetzler$776,711
Others in their field
Top investigators on “Saccharomyces Cerevisiae”
- Ronald Wayne Davis · Stanford University$52,493,521
- Joe Michael Cherry · Stanford University$41,714,975
- Hiten D Madhani · University Of California, San Francisco$22,022,983
- Mark Hochstrasser · University Of Chicago$20,852,291
- Stephen K Burley · Rockefeller University$20,385,391
- Richard D Kolodner · Dana-Farber Cancer Institute$19,307,749
Research focus
Saccharomyces CerevisiaeCytotoxicityDrug Screening /EvaluationCyclohexane /Cyclohexene CarboxylateFungal GeneticsDna Replication OriginAntineoplasticsCell CycleDna DamageMolecular CloningHydroxyureaDna ReplicationDrug Discovery /IsolationAlkylating AgentsGenetic ManipulationCytogeneticsChromatinMcf7 CellGene MutationImmunoprecipitationNeoplastic CellDna FootprintingCell ProliferationAdduct
Grant awards (11)
A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide$24,915
R03 · FY2009 · MH · contact PI
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS$205,284
R01 · FY2004 · CA
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS$199,307
R01 · FY2003 · CA
ANTITUMOR DRUGS AND INHIBITION OF INITIATION OF DNA REPL$185,958
R01 · FY2003 · CA
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS$193,500
R01 · FY2002 · CA
ANTITUMOR DRUGS AND INHIBITION OF INITIATION OF DNA REPL$180,542
R01 · FY2002 · CA
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS$187,864
R01 · FY2001 · CA
ANTITUMOR DRUGS AND INHIBITION OF INITIATION OF DNA REPL$175,283
R01 · FY2001 · CA
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS$207,741
R01 · FY2000 · CA
CHROMOSOMAL TRANSLOCATIONS CAUSED BY TOPO II INHIBITORS$190,311
R01 · FY2000 · CA
ANTITUMOR DRUGS AND INHIBITION OF INITIATION OF DNA REPL$174,858
R01 · FY2000 · CA